These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

198 related items for PubMed ID: 14529881

  • 1. The role of the protocol biopsies in renal allograft recipients.
    Baczkowska T, Perkowska-Francka A, Durlik M, Cieciura T, Nowacka-Cieciura E, Pazik J, Lewandowska D, Mroz A, Matlosz B, Chmura A, Galazka Z, Lao M.
    Transplant Proc; 2003 Sep; 35(6):2179-81. PubMed ID: 14529881
    [Abstract] [Full Text] [Related]

  • 2. Serum TGF-beta1 correlates with chronic histopathological lesions in protocol biopsies of kidney allograft recipients.
    Baczkowska T, Perkowska-Ptasińska A, Sadowska A, Lewandowski Z, Nowacka-Cieciura E, Cieciura T, Pazik J, Lewandowska D, Mroz A, Urbanowicz A, Nazarewski S, Danielewicz R.
    Transplant Proc; 2005 Mar; 37(2):773-5. PubMed ID: 15848527
    [Abstract] [Full Text] [Related]

  • 3. Cyclosporine sparing with mycophenolate mofetil, daclizumab and corticosteroids in renal allograft recipients: the CAESAR Study.
    Ekberg H, Grinyó J, Nashan B, Vanrenterghem Y, Vincenti F, Voulgari A, Truman M, Nasmyth-Miller C, Rashford M.
    Am J Transplant; 2007 Mar; 7(3):560-70. PubMed ID: 17229079
    [Abstract] [Full Text] [Related]

  • 4. Impact of daclizumab, low-dose cyclosporine, mycophenolate mofetil and steroids on renal function after kidney transplantation.
    Fangmann J, Arns W, Marti HP, Hauss J, Ketteler M, Beckurts T, Boesmueller C, Pohanka E, Martin PY, Gerhardt M, Farese S, Neumayer HH, Floege J, Gurr C, Budde K, DACH Study Group.
    Nephrol Dial Transplant; 2010 Jan; 25(1):283-92. PubMed ID: 19773417
    [Abstract] [Full Text] [Related]

  • 5. Prevention of early acute rejection with daclizumab and triple immunosuppression in cadaveric renal allograft recipients.
    Kandus A, Grego K, Bren AF.
    Ther Apher Dial; 2005 Jun; 9(3):262-4. PubMed ID: 15967003
    [Abstract] [Full Text] [Related]

  • 6. IL-2 receptor blockers in liver transplantation: initial experience with daclizumab in Chile.
    Innocenti F, Humeres R, Zamboni M, Sanhueza E, Zapata R, Hepp J, Rius M.
    Transplant Proc; 2003 Nov; 35(7):2520-1. PubMed ID: 14612001
    [Abstract] [Full Text] [Related]

  • 7. [Cytokines and growth factors serum level and renal allograft function (preliminary report)].
    Baczkowska T, Durlik M, Perkowska A, Sadowska A, Cieciura T, Nowacka-Cieciura E, Pazik J, Matłosz B, Wierzbicki P, Kłosowska D, Nowaczyk M, Lao M.
    Pol Merkur Lekarski; 2003 Oct; 15(88):356-8; discussion 358-9. PubMed ID: 14974365
    [Abstract] [Full Text] [Related]

  • 8. Modifying cyclosporine associated renal allograft dysfunction.
    Mohapatra N, Vanikar AV, Patel RD, Trivedi HL.
    Saudi J Kidney Dis Transpl; 2009 Sep; 20(5):770-4. PubMed ID: 19736471
    [Abstract] [Full Text] [Related]

  • 9. Cyclosporine-sparing effects of daclizumab in renal allograft recipients.
    Ingle GR, Moudgil A, Vo A, Jordan SC.
    Am J Health Syst Pharm; 2005 Feb 15; 62(4):391-6. PubMed ID: 15745891
    [Abstract] [Full Text] [Related]

  • 10. Promising early outcomes with a novel, complete steroid avoidance immunosuppression protocol in pediatric renal transplantation.
    Sarwal MM, Yorgin PD, Alexander S, Millan MT, Belson A, Belanger N, Granucci L, Major C, Costaglio C, Sanchez J, Orlandi P, Salvatierra O.
    Transplantation; 2001 Jul 15; 72(1):13-21. PubMed ID: 11468528
    [Abstract] [Full Text] [Related]

  • 11. Avoidance of cyclosporine in renal transplantation: effects of daclizumab, mycophenolate mofetil, and steroids.
    Tran HTB, Acharya MK, McKay DB, Sayegh MH, Carpenter CB, Auchincloss H, Kirkman RL, Milford EL.
    J Am Soc Nephrol; 2000 Oct 15; 11(10):1903-1909. PubMed ID: 11004222
    [Abstract] [Full Text] [Related]

  • 12. Multicenter trial exploring calcineurin inhibitors avoidance in renal transplantation.
    Vincenti F, Ramos E, Brattstrom C, Cho S, Ekberg H, Grinyo J, Johnson R, Kuypers D, Stuart F, Khanna A, Navarro M, Nashan B.
    Transplantation; 2001 May 15; 71(9):1282-7. PubMed ID: 11397963
    [Abstract] [Full Text] [Related]

  • 13. Comparison of four different immunosuppression protocols without long-term steroid therapy in kidney recipients monitored by surveillance biopsy: five-year outcomes.
    Anil Kumar MS, Irfan Saeed M, Ranganna K, Malat G, Sustento-Reodica N, Kumar AM, Meyers WC.
    Transpl Immunol; 2008 Nov 15; 20(1-2):32-42. PubMed ID: 18773960
    [Abstract] [Full Text] [Related]

  • 14. Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. U.S. Renal Transplant Mycophenolate Mofetil Study Group.
    Sollinger HW.
    Transplantation; 1995 Aug 15; 60(3):225-32. PubMed ID: 7645033
    [Abstract] [Full Text] [Related]

  • 15. Pharmacokinetics of daclizumab and mycophenolate mofetil with cyclosporine and steroids in renal transplantation.
    Pescovitz MD, Bumgardner G, Gaston RS, Kirkman RL, Light S, Patel IH, Nieforth K, Vincenti F.
    Clin Transplant; 2003 Dec 15; 17(6):511-7. PubMed ID: 14756266
    [Abstract] [Full Text] [Related]

  • 16. Basiliximab versus daclizumab combined with triple immunosuppression in deceased donor renal graft recipients.
    Grego K, Arnol M, Bren AF, Kmetec A, Tomaziĉ J, Kandus A.
    Transplant Proc; 2007 Dec 15; 39(10):3093-7. PubMed ID: 18089329
    [Abstract] [Full Text] [Related]

  • 17. Continued superior outcomes with modification and lengthened follow-up of a steroid-avoidance pilot with extended daclizumab induction in pediatric renal transplantation.
    Sarwal MM, Vidhun JR, Alexander SR, Satterwhite T, Millan M, Salvatierra O.
    Transplantation; 2003 Nov 15; 76(9):1331-9. PubMed ID: 14627912
    [Abstract] [Full Text] [Related]

  • 18. Basiliximab versus daclizumab combined with triple immunosuppression in deceased donor renal transplantation: a prospective, randomized study.
    Kandus A, Arnol M, Omahen K, Oblak M, Vidan-Jeras B, Kmetec A, Bren AF.
    Transplantation; 2010 Apr 27; 89(8):1022-7. PubMed ID: 20075788
    [Abstract] [Full Text] [Related]

  • 19. Early steroid withdrawal protocol with basiliximab, cyclosporine and mycophenolate mofetil in renal-transplant recipients.
    Kato Y, Tojimbara T, Iwadoh K, Koyama I, Nanmoku K, Kai K, Sannomiya A, Nakajima I, Fuchinoue S, Teraoka S.
    Int Immunopharmacol; 2006 Dec 20; 6(13-14):1984-92. PubMed ID: 17161352
    [Abstract] [Full Text] [Related]

  • 20. Randomized trial of three different immunosuppressive regimens to prevent chronic renal allograft rejection.
    Burke GW, Ciancio C, Blomberg BB, Rosen A, Suzart K, Roth D, Kupin W, Esquenazi V, Miller J.
    Transplant Proc; 2002 Aug 20; 34(5):1610-1. PubMed ID: 12176505
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.